Dr. Robinson graduated with her Pharm.D. from the University of Tennessee Health Science Center in 2019. She then completed a PGY1 residency at the University of Kentucky and a PGY2 residency in Clinical Pharmacogenomics at St. Jude Children's Research Hospital. Her clinical interests include effective implementation of pharmacogenomics to improve outcomes using implementation science techniques. Her research interests include identifying determinants of variability in high-risk medications to personalize therapy.
Robinson KM, Yang W, Karol SE, Kornegay N, Jay D, Cheng C, Choi JK, Campana D, Pui C, Wood B, Borowitz MJ, Gastier-Foster J, Larsen EC, Winick N, Carroll WL, Loh ML, Raetz EA, Hunger SP, Devidas M, Mardis ER, Fulton RS, Relling MV, Jeha S. No evidence that G6PD deficiency affects the efficacy or safety of daunorubicin in acute lymphoblastic leukemia induction therapy. Pediatr Blood and Cancer; 2019; 66(6): e27681.
Robinson KM, Yang W, Haidar CE, Hankins JS, Jay DW, Kornegay N, Rubnitz JE, Broeckel U, Cheng C, Pui C, Jeha S, Relling MV. Concordance between glucose-6-phosphate-dehydrogenase (G6PD) genotype and phenotype and rasburicase use in patients with hematologic malignancies. Pharmacogenomics Journal; 2018: doi:10.1038/s41397-018-0043-3.
“Optimizing Oncology Care With Germline Pharmacogenomics:
Case-Based Education for Oncology Practitioners." ISCC-PEG Annual Meeting 2022; Virtual
Robinson KM, Prebehalla LR, Coons JC, Empey PE. Opportunity to optimize CYP2C19-guided antiplatelet prescribing during transitions of care. Poster presented at Clinical Pharmacogenetics Implementation Consortium/Pharmacogenomics Global Research Network Meeting; 2022 May 10-12; Aurora, CO.
